Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) today announced positive results from its Phase 2b clinical trial of topical ocular reproxalap ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE